The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
960
October 27, 1995
View Complete Issue         Table of Contents 2019 
Nalmefene - Long-Acting Injectable Opioid Antagonist
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Nalmefene - Long-Acting Injectable Opioid Antagonist
October 27, 1995 (Issue: 960)
Nalmefene (Revex - Ohmeda), an i methylene analog of naltrexone (Trexan), is a long-acting opioid antagonist that has been approved by the US Food and Drug Administration for reversal of postoperative opioid drug effects, including respiratory...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Nalmefene - Long-Acting Injectable Opioid Antagonist
Article code: 960c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.